

## Disclosures

### Personal Commercial (21)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
35Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Abbott	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Abiomed	Other - travel reimbursement for research meeting	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Acorai	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Adona	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Alleviant	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Aria CV	Stock	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
CVRx	Other - travel for research meeting	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Edwards LifeSciences	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Endotronix	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Fauna Bio	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Gradient	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Imbria	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Merck	Other - Hemodynamic Core Lab; steering committee	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Morphic Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Pulmonvant	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Restore Medical	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Tempus AI	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
United Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Task Force Co-Chair for WSPH - PH due to left heart disease	Other	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic

### Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
ALIVE study	bioventrix	
Social HF	National Institutes of Health	National Institutes of Health
VENUS HF	Precardia	

# Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (6)

Year	Case Title	Represented	Description	Compensation
<b>Self</b>				
2021	cardiorespiratory arrest	Defendant		Significant (>= \$5,000)
2020	hyperkalemia	Defendant		Significant (>= \$5,000)
2019	aortic stenosis	Defendant	Cases of critical AS	Significant (>= \$5,000)
2017	heart failure	Defendant		Significant (>= \$5,000)
2016	heart failure/SCD	Defendant	death from arrhythmia	Modest (< \$5,000)
2016	acute coronary syndrome	Plaintiff † Lawfirm	Sudden death	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 10/1/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.